CIK 0000320017
- Non-accelerated filer
- Smaller reporting company
LISATA THERAPEUTICS, INC.
Sign in to watch- Ticker
- LSTA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 222343568
- Phone
- +1 908-229-2590
- Business address
- 110 ALLEN ROAD, SECOND FLOOR, BASKING RIDGE, NJ, 07920
- Former names
- Caladrius Biosciences, Inc., CALADRIUS BIOSCIENCES, INC., NeoStem, Inc., PHASE III MEDICAL INC/DE, CORNICHE GROUP INC /DE
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-14 | Girolamo Todd C CLO, SVP of Corp Dev | Shares withheld for taxes | −2,158 | $0.82 | $2K | 160,827 |
| 2022-01-14 | Mazzo David J Chief Executive Officer | Shares withheld for taxes | −6,611 | $0.82 | $5K | 631,065 |
| 2022-01-13 | Girolamo Todd C CLO, SVP of Corp Dev | Shares withheld for taxes | −2,563 | $0.81 | $2K | 162,985 |
| 2022-01-13 | Mazzo David J Chief Executive Officer | Shares withheld for taxes | −6,471 | $0.81 | $5K | 637,676 |
| 2022-01-11 | Girolamo Todd C CLO, SVP of Corp Dev | Shares withheld for taxes | −4,722 | $0.87 | $4K | 165,548 |
| 2022-01-11 | Mazzo David J Chief Executive Officer | Shares withheld for taxes | −16,740 | $0.87 | $14K | 644,147 |
| 2022-01-10 | Girolamo Todd C CLO, SVP of Corp Dev | Grant or award | +129,000 | 187,675 | ||
| 2022-01-10 | Girolamo Todd C CLO, SVP of Corp Dev | Shares withheld for taxes | −17,405 | $0.92 | $16K | 170,270 |
| 2022-01-10 | Girolamo Todd C CLO, SVP of Corp Dev | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2022-01-10 | Buck Kristen K EVP, R&D and CMO | Grant or award | +64,500 | 326,897 | ||
| 2022-01-10 | Buck Kristen K EVP, R&D and CMO | Shares withheld for taxes | −7,694 | $0.92 | $7K | 319,203 |
| 2022-01-10 | Buck Kristen K EVP, R&D and CMO | Grant or award · Stock Option (Right to Buy) | +32,500 | 32,500 | ||
| 2022-01-10 | Flowers Cynthia Louise Director | Grant or award | +65,430 | 145,847 | ||
| 2022-01-10 | Whitaker Anne Clem Director | Grant or award | +65,430 | 182,635 | ||
| 2022-01-10 | Davidson Michael H. Director | Grant or award | +65,430 | 209,753 | ||
| 2022-01-10 | BROWN GREGORY B Director | Grant or award | +65,430 | 149,040 | ||
| 2022-01-10 | Mazzo David J Chief Executive Officer | Grant or award | +401,000 | 717,297 | ||
| 2022-01-10 | Mazzo David J Chief Executive Officer | Shares withheld for taxes | −56,410 | $0.92 | $52K | 660,887 |
| 2022-01-10 | Mazzo David J Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2022-01-10 | TRABER PETER G Director | Grant or award | +65,430 | 149,190 |
Page 6 of 18 · 345 trades